Clinical Trial Update: Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD) [Phase 2, Phase 3]

View source ↗

Summary

This document reports completion of Phase 2 and Phase 3 trials evaluating indacaterol delivered via a single-dose dry powder inhaler for chronic obstructive pul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Indacaterol (indacaterol)

Snippet

Sponsor: Novartis | Conditions: Pulmonary Disease, Chronic Obstructive, COPD | Phase 2, Phase 3 | Status: COMPLETED